{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:10:23Z","timestamp":1791537023417,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003646","name":"National Health Insurance Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No.2022R1A2C1012252"],"award-info":[{"award-number":["No.2022R1A2C1012252"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No.2022R1A2C1012252"],"award-info":[{"award-number":["No.2022R1A2C1012252"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No.2022R1A2C1012252"],"award-info":[{"award-number":["No.2022R1A2C1012252"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-12207-9","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:28:16Z","timestamp":1736814496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada"],"prefix":"10.1186","volume":"25","author":[{"given":"Jihyung","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"12207_CR1","unstructured":"NHS England. NHS treats first patient with the \u2018world\u2019s most expensive drug. 2021. https:\/\/www.england.nhs.uk\/2021\/06\/nhs-treats-first-patient-with-the-worlds-most-expensive-drug\/. Accessed 02.05 2023."},{"key":"12207_CR2","unstructured":"Cumbers J. Why Some Drugs Cost $2.1 Million Per Dose And How One Company Plans To Change This. 2021. https:\/\/www.forbes.com\/sites\/johncumbers\/2021\/12\/16\/why-some-drugs-cost-21-million-per-dose-and-how-one-company-plans-to-change-this\/?sh=7972d5dc8953. Accessed 02.05 2023."},{"key":"12207_CR3","unstructured":"Drugs.com. 10 of the Most Expensive Drugs in the U.S. https:\/\/www.drugs.com\/article\/top-10-most-expensive-drugs.html. Accessed 19.10 2024. 2024. Accessed"},{"key":"12207_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","volume":"23","author":"M Dabbous","year":"2020","unstructured":"Dabbous M, Chachoua L, Caban A, Toumi M. Managed Entry Agreements: Policy Analysis From the European Perspective. Value Health. 2020;23:425\u201333.","journal-title":"Value Health"},{"key":"12207_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fphar.2018.00280","volume":"9","author":"JC Bouvy","year":"2018","unstructured":"Bouvy JC, Sapede C, Garner S. Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe. Front Pharmacol. 2018;9:280.","journal-title":"Front Pharmacol"},{"key":"12207_CR6","unstructured":"Safety MoFaD. Revision of guidelines for the application of expedited review of drugs 2021. https:\/\/www.mfds.go.kr\/brd\/m_218\/view.do?seq=33421&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1. Accessed 02.05 2023."},{"key":"12207_CR7","unstructured":"Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states. In. Paris; 2019."},{"key":"12207_CR8","doi-asserted-by":"publisher","first-page":"888404","DOI":"10.3389\/fmedt.2022.888404","volume":"4","author":"E Xoxi","year":"2022","unstructured":"Xoxi E, Rumi F, Kanavos P, Dauben HP, Gutierrez-Ibarluzea I, Wong O, Rasi G, Cicchetti A. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. Front Med Technol. 2022;4:888404.","journal-title":"Front Med Technol"},{"key":"12207_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/rme-2020-0169","volume":"16","author":"J Jorgensen","year":"2021","unstructured":"Jorgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16:405\u201322.","journal-title":"Regen Med"},{"key":"12207_CR10","doi-asserted-by":"publisher","first-page":"699466","DOI":"10.3389\/fphar.2021.699466","volume":"12","author":"E Xoxi","year":"2021","unstructured":"Xoxi E, Facey KM, Cicchetti A. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. Front Pharmacol. 2021;12:699466.","journal-title":"Front Pharmacol"},{"key":"12207_CR11","unstructured":"NHS England. Cancer Drugs Fund. 2023. https:\/\/www.england.nhs.uk\/cancer\/cdf\/. Accessed 02.05 2023."},{"key":"12207_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","volume":"35","author":"A Ferrario","year":"2017","unstructured":"Ferrario A, Araja D, Bochenek T, Catic T, Danko D, Dimitrova M, Furst J, Greiciute-Kuprijanov I, Hoxha I, Jakupi A, et al. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics. 2017;35:1271\u201385.","journal-title":"Pharmacoeconomics"},{"key":"12207_CR13","unstructured":"Health Insurance Review and Assessment. Regulations on evaluation criteria and procedures for deciding reimbursement eligibility criteria (\uc57d\uc81c\uc758 \uc694\uc591\uae09\uc5ec\ub300\uc0c1\uc5ec\ubd80 \ub4f1\uc758 \ud3c9\uac00\uae30\uc900 \ubc0f \uc808\ucc28 \ub4f1\uc5d0 \uad00\ud55c\uaddc\uc815 in Korean). 2022. https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA040055000000&WT.gnb=%EC%8B%AC%EC%82%AC%ED%8F%89%EA%B0%80%EC%9B%90%EB%82%B4%EB%B6%80%EA%B7%9C%EC%A0%95. Accessed 02.20 2023."},{"key":"12207_CR14","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluation topic selection: the manual 2022. https:\/\/www.nice.org.uk\/process\/pmg37\/chapter\/highly-specialised-technologies. Accessed 04.20 2023."},{"key":"12207_CR15","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual 2022. www.nice.org.uk\/process\/pmg36 Accessed 04.20 2023."},{"key":"12207_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40258-022-00778-1","volume":"21","author":"IH Lee","year":"2023","unstructured":"Lee IH, Bloor K, Bae EY. A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England. Appl Health Econ Health Policy. 2023;21:347\u201359.","journal-title":"Appl Health Econ Health Policy"},{"key":"12207_CR17","volume-title":"The pharmaceutical price regulation scheme 2009","author":"Department of Health","year":"2008","unstructured":"Department of Health. The pharmaceutical price regulation scheme 2009. London: Department of Health; 2008."},{"key":"12207_CR18","unstructured":"NHS England. Innovative Medicines Fund. 2023. https:\/\/www.england.nhs.uk\/medicines-2\/innovative-medicines-fund\/. Accessed 02.20 2023."},{"key":"12207_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.vhri.2020.09.001","volume":"24","author":"H Kim","year":"2021","unstructured":"Kim H, Byrnes J, Goodall S. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee. Value in health regional issues. 2021;24:6\u201311.","journal-title":"Value in health regional issues"},{"key":"12207_CR20","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","volume":"21","author":"S Wang","year":"2018","unstructured":"Wang S, Gum D, Merlin T. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed? Value Health. 2018;21:938\u201343.","journal-title":"Value Health"},{"key":"12207_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","volume":"36","author":"HW Tuffaha","year":"2018","unstructured":"Tuffaha HW, Scuffham PA. The Australian Managed Entry Scheme: Are We Getting it Right? Pharmacoeconomics. 2018;36:555\u201365.","journal-title":"Pharmacoeconomics"},{"key":"12207_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1017\/S0266462317001106","volume":"34","author":"MF Robinson","year":"2018","unstructured":"Robinson MF, Mihalopoulos C, Merlin T, Roughead E. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA. Int J Technol Assess Health Care. 2018;34:46\u201355.","journal-title":"Int J Technol Assess Health Care"},{"key":"12207_CR23","unstructured":"Department of Health and Aged Care. Life Saving Drugs Program. 2023. https:\/\/www.health.gov.au\/our-work\/life-saving-drugs-program\/about-the-lsdp. Accessed 02.05 2023."},{"key":"12207_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CEOR.S134230","volume":"9","author":"EM Adkins","year":"2017","unstructured":"Adkins EM, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? ClinicoEconomics and outcomes research\u202f: CEOR. 2017;9:327\u201342.","journal-title":"ClinicoEconomics and outcomes research : CEOR"},{"key":"12207_CR25","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/curroncol29020100","volume":"29","author":"DJ Stewart","year":"2022","unstructured":"Stewart DJ, Bradford JP, Batist G. Treatment Access, Health Economics, and the Wave of a Magic Wand. Current oncology (Toronto, Ont). 2022;29:1176\u201389.","journal-title":"Current oncology (Toronto, Ont)"},{"key":"12207_CR26","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/curroncol29030156","volume":"29","author":"S Sehdev","year":"2022","unstructured":"Sehdev S, Chambers A. Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021. Current oncology (Toronto, Ont). 2022;29:1919\u201331.","journal-title":"Current oncology (Toronto, Ont)"},{"key":"12207_CR27","doi-asserted-by":"publisher","unstructured":"OECD. Purchasing power parities (PPP) (indicator). https:\/\/doi.org\/10.1787\/1290ee5a-en 2023. https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm. Accessed 05.05 2023.","DOI":"10.1787\/1290ee5a-en"},{"key":"12207_CR28","unstructured":"Lee T, Bae E-Y, Son K-B, Lee H-J, Hong J. Study on the Evaluation and Future Directions of the Risk-Sharing Agreement System (2022-2-000). In. Seoul: Seoul National University Industry-Academia Cooperation Foundation & National Health Insurance Service; 2022."},{"key":"12207_CR29","doi-asserted-by":"crossref","unstructured":"Efthymiadou O. Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries. Eur J Health Econ.\u00a02023;24(7):1023\u201331.","DOI":"10.1007\/s10198-022-01526-x"},{"key":"12207_CR30","unstructured":"Health Insurance Review Assessment Service. Appraisal documents published by HIRA. https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014040000. Accessed 02.05 2023."},{"key":"12207_CR31","unstructured":"National Institute for Health and Care Excellence. Guidance, NICE advice and quality standards (Technology appraisal guidance). https:\/\/www.nice.org.uk\/guidance\/published?ngt=Technology%20appraisal%20guidance&ndt=Guidance. Accessed 02.05 2023."},{"key":"12207_CR32","unstructured":"Pharmaceutical Benefits Advisory Committee. Public Summary Documents of PBAC meetings. https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/. Accessed 02.05 2023."},{"key":"12207_CR33","unstructured":"Medical Services Advisory Committee. Public Summary Documents of MSAC meetings. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf. Accessed 02.05 2023."},{"key":"12207_CR34","unstructured":"Canadian Agency for Drugs Technologies in Health. Reimbursement Review Reports. https:\/\/www.cadth.ca\/reimbursement-review-reports. Accessed 02.05 2023."},{"key":"12207_CR35","unstructured":"NHS England. Clinical Commissioning Policy: Use of defibrotide in severe venoocclusive disease following stem cell transplant. 2021. https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2015\/01\/b04-use-defibrotide.pdf. Accessed 02.05 2023."},{"key":"12207_CR36","unstructured":"Department of Health and Aged Care. About the Life Saving Drugs Program. 2023. https:\/\/www.health.gov.au\/our-work\/life-saving-drugs-program\/about-the-lsdp. Accessed May 09 2023."},{"key":"12207_CR37","unstructured":"Canadian Agency for Drugs and Technologies in Health. Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations. 2022. https:\/\/www.cadth.ca\/tisagenlecleucel-acute-lymphoblastic-leukemia-and-diffuse-large-b-cell-lymphoma-recommendations. Accessed 11.20 2022."},{"key":"12207_CR38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13023-016-0539-3","volume":"11","author":"G Janoudi","year":"2016","unstructured":"Janoudi G, Amegatse W, McIntosh B, Sehgal C, Richter T. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review. Orphanet J Rare Dis. 2016;11:164.","journal-title":"Orphanet J Rare Dis"},{"key":"12207_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13023-018-0759-9","volume":"13","author":"JI McCormick","year":"2018","unstructured":"McCormick JI, Berescu LD, Tadros N. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand. Orphanet J Rare Dis. 2018;13:27.","journal-title":"Orphanet J Rare Dis"},{"key":"12207_CR40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"FM Clement","year":"2009","unstructured":"Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302:1437\u201343.","journal-title":"JAMA"},{"key":"12207_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.healthpol.2012.09.012","volume":"108","author":"E Nicod","year":"2012","unstructured":"Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy. 2012;108:167\u201377.","journal-title":"Health Policy"},{"key":"12207_CR42","unstructured":"Ministry of Health Long-Term Care. Ontario Public Drug Programs. Annual Report 2017. In. Ontario: Office of the Auditor General of Ontario; 2017."},{"key":"12207_CR43","unstructured":"National Institute for Health and Care Excellence. Elosulfase alfa for treating mucopolysaccharidosis type 4A. 2022. https:\/\/www.nice.org.uk\/guidance\/hst19. Accessed 02.05 2023."},{"key":"12207_CR44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s13023-021-01876-4","volume":"16","author":"B Stevens","year":"2021","unstructured":"Stevens B, Kenny T, Thomas S, Morrison A, Jarrett J, Jain M. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement. Orphanet J Rare Dis. 2021;16:394.","journal-title":"Orphanet J Rare Dis"},{"key":"12207_CR45","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION. ELOSULFASE ALFA RESUBMISSION 2016. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0456_complete_Vimizim_May-26_16.pdf. Accessed 02.05 2023."},{"key":"12207_CR46","unstructured":"Hong J. What should a cost-effectiveness threshold reflect? Review on the implications and determinants of the threshold. The 2021 autumn meeting of the Korean Association of Health Technology Assessment (oral presentation). 2021."},{"key":"12207_CR47","unstructured":"National Institute for Health and Care Excellence. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma. 2023. https:\/\/www.nice.org.uk\/guidance\/ta524. Accessed 02.05 2023."},{"key":"12207_CR48","unstructured":"National Institute for Health and Care Excellence. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. 2022. https:\/\/www.nice.org.uk\/guidance\/ta783. Accessed 02.05 2023."},{"key":"12207_CR49","unstructured":"National Institute for Health and Care Excellence. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. 2022. https:\/\/www.nice.org.uk\/guidance\/ta784. Accessed 12.05 2022."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12207-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:28:30Z","timestamp":1736814510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12207-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12207"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12207-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}